Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: A meta-analysis

Journal of Clinical Pharmacy and Therapeutics

Volumn 38, Issue 4, 2013, Pages 301-308

  Feng, X ^a   Dong, K ^a   Pham, D ^a   Pence, S ^a   Inciardi, J ^a   Bhutada, N S ^a  

^a CALIFORNIA NORTHSTATE UNIVERSITY   (United States)

Author keywords

allopurinol; rasburicase; tumour lysis syndrome

Indexed keywords

ALLOPURINOL; RASBURICASE; URIC ACID;

ARTICLE; CANCER PATIENT; DRUG COST; DRUG EFFICACY; HUMAN; HYPERURICEMIA; META ANALYSIS; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL;

ALLOPURINOL; RASBURICASE; TUMOUR LYSIS SYNDROME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; FEMALE; HUMANS; HYPERURICEMIA; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TUMOR LYSIS SYNDROME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; URATE OXIDASE; URIC ACID; YOUNG ADULT;

EID: 84879894322     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12061     Document Type: Article

References (37)

1. Mughal TI, Ejaz AA, Foringer JR, Coiffier B,. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev, 2010; 36: 164-176.
2. Muslimani A, Chisti MM, Wills S, et al,. How we treat tumor lysis syndrome. Oncology (Williston Park), 2011; 4: 369-375.
3. Hochberg J, Cairo MS,. Tumor lysis syndrome: current perspective. Haematologica, 2008; 93: 9-13.
4. Rampello E, Fricia T, Malaguarnera M,. The management of tumor lysis syndrome. Nat Clin Pract Oncol, 2006; 3: 438-447.
5. Rajendran A, Bansal D, Marwaha RK, Singhi SC,. Tumor lysis syndrome. Indian J Pediatr, 2012; 1: 50-54.
6. Kekre N, Djordjevic B, Touchie C, Spontaneous tumour lysis syndrome. CMAJ, 2012; 8: 913-916.
7. Cairo MS, Bishop M,. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol, 2004; 127: 3-11.
8. Yim BT, Sims-McCallum RP, Chong PH,. Rasburicase for the treatment and prevention of hyperuricemia. Ann Pharmacother, 2003; 37: 1047-1054.
9. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS,. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol, 2008; 26: 2767-2778.
10. Coiffier B, Mounier N, Bologna S, et al,.; Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol, 2003; 21: 4402-4406.
11. Jeha S, Kantarjian H, Irwin D, et al,. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia, 2005; 19: 34-38.
12. Cortes J, Moore JO, Maziarz RT, et al,. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone-Results of a multicenter phase III study. J Clin Oncol, 2010; 20: 4207-4213.
13. Darmon M, Guichard I, Vincent F,. Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration. J Clin Oncol, 2011; 29: e67-e68.
14. Cortes J., Reply to M. Darmon et al. J Clin Oncol, 2011; 29: e69.
15. Arnold TM, Reuter JP, Delman BS, Shanholtz CB,. Use of single-dose rasburicase in an obese female. Ann Pharmacother, 2004; 38: 1428-1431.
16. Hooman N, Otukesh H,. Single dose of rasburicase for treatment of hyperuricemia in acute kidney injury: a report of 3 cases. Iran J Kidney Dis, 2011; 5: 130-132.
17. Vines AN, Shanholtz CB, Thompson JL,. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients. Ann Pharmacother, 2010; 44: 1529-1537.
18. McDonnell AM, Lenz KL, Frei-Lahr DA, Hayslip J, Hall PD,. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy, 2006; 26: 806-812.
19. Giraldez M, Puto KA,. Single fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults Eur J Haematol, 2010; 85: 177-179.
20. Hummel M, Buchheidt D, Reiter S, Bergmann J, Adam K, Hehlmann R,. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia-successful treatment and prevention of TLS with low-dose rasburicase. Eur J Haematol, 2005; 75: 518-521.
21. Malaguarnera M, Vacante M, Dipasquale G, Gargante MP, Motta M,. A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function. Expert Opin Pharmacother, 2009; 10: 737-742.
22. Hummel M, Buchheidt D, Bergmann J, Hofheinz R, Hehlmann R,. Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome. Leukemia, 2003; 17: 2542-2544.
23. Trifilio S, Pi J, Zook J, et al,. Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies. Bone Marrow Transplant, 2011; 46: 800-805.
24. Liu CY, Sims-McCallum RP, Schiffer CA,. A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leuk Res, 2005; 29: 463-465.
25. Vadhan-Raj S, Fayad LE, Fanale MA, et al,. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol, 2012; 23: 1640-1645.
26. Reeves D, Bestul D,. Evaluation of a Single Fixed Dose of Rasburicase 7.5 mg for the Treatment of Hyperuricemia in Adults with Cancer. Pharmacotherapy, 2008; 28: 685-690.
27. Knoebel RW, Lo M,., Crank CW,. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome. J Oncol Pharm Pract, 2011; 17: 147-54.
28. Campara M, Shord SS, Haaf CM,. Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach. J Clin Pharm Ther, 2009; 34: 207-213.
29. Chiang J, Chan A, Lian T, et al. Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review. Asia Pac J Clin Oncol, 2011; 7: 351-356.
30. Steel S, Coutsouvelis J, Mckendrick J,. Single dose rasburicase in tumor lysis: One hospital's experience. Asia Pac J Clin Oncol, 2008; 4: 18-20.
31. Montesinos P, Lorenzo I, Martín G, Sanz J, Pérez-Sirvent ML,. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica, 2008; 93: 67-74.
32. Goldman SC, Holcenberg JS, Finklestein JZ, et al,. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood, 2001; 97: 2998.
33. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS,. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol, 2008; 26: 2767-2778.
34. Hiatt RA, Fireman BH,. Serum uric acid unrelated to cancer incidence in humans. Cancer Res, 1988; 48: 2916-2918.
35. Trifilio S, Gordon L, Singhal S, et al,. Reduced -dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant, 2006; 37: 997-1001.
36. Ueng S,. Rasburicase (Elitek): a novel agent for tumor lysis syndrome. Proc (Bayl Univ Med Cent), 2005; 18: 275-279.
37. Pession A, Melchionda F, Castellini C, Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase). Biologics, 2008; 2: 129-141.